
Opinion|Videos|May 19, 2025
Treatment or Lack of Treatment of Small Renal Masses
Explore treatment options for small renal masses, including surveillance, surgery, and biopsy, while understanding the role of ccRCC PET in diagnosis.
Advertisement
Episodes in this series

Treatment Approaches and Role of Biopsy
Main Discussion Topics:
- Masses under 2 cm are typically managed with active surveillance.
- Options for masses that are 2 to 4 cm include ablation (eg, cryotherapy, radiofrequency ablation) and surgical approaches.
- Kidney cancer is often treated without tissue diagnosis, unlike most other cancers.
- Biopsy utilization depends on tumor characteristics and management implications.
Key Points for Physicians:
- Small masses (< 2cm) are generally appropriate for active surveillance.
- Approximately 60% to 70% of small renal masses are malignant.
- Biopsy is considered for unusual lesions, suspected metastases, or infiltrative patterns.
- Risk stratification can be enhanced by considering patient age, gender, and tumor size.
Notable Insights:
Kidney cancer remains one of the few cancers typically treated without tissue confirmation, though this approach is increasingly being questioned.
Clinical Significance:
Size-based management algorithms provide practical guidance, but patient-specific factors and tumor characteristics should inform individualized treatment decisions.
Advertisement
Related to this article

Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.

A national study found that use of MRI before prostate biopsy increased in US hospitals from 2017 through the first half of 2026.

The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.

The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.

The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.

Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.
Advertisement
Advertisement
Trending on Urology Times
1
Evidence for Combining Prostatic Urethral Lift With Radiotherapy
2
FDA grants breakthrough device designation to urine ID/AST panel
3
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
4
Use of prebiopsy prostate MRI increasing across US hospitals, study finds
5

